fda glp-1 warning 2025 november Sends Letters to More Than 50 Compounders and Manufacturers Exploration of the potential association

Our providers listen first, then help you find a path that works, whether thats injectable GLP-1s now or oral options as they become available through our programs

Clinicians monitor for gastrointestinal tolerance and renal function during treatment

Using GLP-1 treatment with insulin or certain diabetes medicines may increase the risk of low blood sugar

The "maintained improvements" group (approximately 30-40% of users) reports substantial benefit retention 6-12 months post-discontinuation, typically characterized by users who completed 6+ month treatment courses using adequate concentrations (1-2% GHK-Cu), maintained consistent application patterns, addressed underlying skin damage during treatment allowing structural improvements, optimized complementary skincare including sun protection and moisturization, maintained healthy lifestyle supporting collagen synthesis including adequate protein intake and sleep, and possessed favorable genetics for collagen production and skin aging resistance

Mediation analysis supports a causal relationship between maternal hyperglycemia and placental DNA methylation variations at the leptin gene locus and cord blood leptin levels